


CIRCUIT FOR THE PREPARATION, CONTROL, AND DISPENSATION OF AUTOLOGOUS SERUM EYE DROPS IN A PHARMACY SERVICE

Gómez-Costa E¹, Feal-Cortizas MB^{1,2}, Mateos-Salvador M¹, Rotea-Salvo S^{1,2}, Luaces-Rodríguez A¹, Caeiro-Martínez L¹, Fernández-Diz C¹, Torres-Pérez A¹, Margusino-Framiñán L^{1,2}, Martín-Herranz MI^{1,2}

1. Pharmacy Department. A Coruña University Hospital Complex (Sergas). Spain
2. Research Group of Hospital Pharmacy. Biomedical Research Institute A Coruña (INIBIC)

WHAT WAS DONE?

Implementation of a circuit for:




WHY WAS DONE?

Autologous serum eye drops are classified as a special medication that must be prepared in authorized centers with an up-to-date patient registry.

This initiative aims to ensure the **safe use of autologous serum eye drops, guaranteeing quality and safety in their preparation and administration.**

HOW WAS IT DONE?

The circuit was established in the Pharmacy Service in 2015.



The pharmacist:

- reviews the microbiological control of each batch and the patient's serological results,
- records batch traceability,
- provides necessary information on storage and administration.

WHAT WAS ACHIEVED?

JAN 2024 → AUG 2024

- 294 Patients
- 477 Blood Extractions
- 11,925 Eye Drops Prepared

Autologous Serum Concentration	Percentage of Eye Drops Prepared	Microbiological control of the eye drops	
20%	76.9%	Negative	False positive
30%	11.5%	98.1%	1.9%
50%	11.2%		
100%	0.4%		

Confirmed by a second negative control

Infectious Diseases Detected in the Serology

- Hepatitis C (1 case)
- Hepatitis B (1 case)
- Syphilis (1 case)

These data reflect a **high success rate in the preparation, the quality control and the effectiveness of the implemented circuit.** Additionally, the system has allowed for the **early detection of viral infections, reinforcing treatment safety.**

WHAT IS NEXT?

The implementation of this circuit has proven **effective in ensuring the safety and efficacy of autologous serum eye drops**, providing rigorous control over treatments and the quality of dispensed products.

Future steps will involve **pharmacists requesting serological tests** and developing **protocols for managing patients with identified infections.** Furthermore, **patient surveys** will evaluate treatment effectiveness and overall patient experience.

